Purespring Therapeutics has raised $105m in a Series B funding round which will help progress its lead candidate PS-002 to ...

London-based biotech Purespring Therapeutics plans to bring their kidney-tweaking gene therapy to the clinic with the help of ...

Biotechnology company Purespring Therapeutics has raised about $105 million to fund its development of gene therapies for ...

Purespring Therapeutics, a UK-based gene therapy company focused on kidney disease, has raised £80 million ($105 million) in ...

Purespring Therapeutics Ltd. has raised £80 million (US$104.6 million) in a series B, putting it on course to be the first to ...

Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseasesOversubscribed financing led ...

The London-based firm said it will use the funds to advance its gene therapy pipeline, including its lead program in IgA nephropathy.

John Maraganore, the former CEO of Alnylam Pharmaceuticals, launched City Therapeutics, a new startup with $135 million from ...

A University of Bristol spinout company focused on transforming the way kidney diseases are treated has announced an £80m ...

Purespring raises £80 million in a Series B financing, with Syncona committing £19.9 million[1] as part of a leading syndicate of life science investorsProceeds will be used to advance Purespring’s ...

Most boys treated with breakthrough gene therapy for a rare but deadly brain illness are faring well six years later, two new ...

Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases ...